With plans to go public in FY25, an Australian biotech company, Filamon, co-founded by a local industry pioneer, is putting itself in a position to be a significant player in combating the "silver tsunami" of age-related diseases.

In order to treat age-related diseases and chronic inflammatory disorders like cancer, dementia, and degenerative eye conditions like macular degeneration and diabetic retinopathies, Filamon is creating next-generation anti-inflammatory medications.

The medications are the result of Australian university biotech innovations and research, for which over A$50 million has been spent on development to date on silver tsunami solutions

Dr. Graham Kelly, the CEO and chairman of Filamon, is a serial entrepreneur and pioneer in Australian biotech. He feels that his latest venture unifies his work over a half-century ago.

Kelly informed reporters that he has spent his entire life working toward this goal since he has been involved in medical research for a long time and has an excellent sense of what could be revolutionary or successful.

In addition to Kelly, the other co-founders of Filamon are Kieran Scott, an associate professor of cancer at Western Sydney University, and executive director Professor Paul de Souza, a professor of medicine at the University of Sydney's Nepean Clinical School. The chair of the scientific advisory board for Filamon is Scott.

Kelly started his career in drug research in the 1970s while pursuing his PhD at the Faculty of Medicine at The University of Sydney. There, he created a groundbreaking medication that was used to cure kidney transplant tissue rejection in thousands of recipients.

Four drug development firms that he started are still in business and are listed on the NASDAQ and ASX.